Roche AG reported Monday that a pivotal trial combining the MEK-inhibitor cobimetinib with Zelboraf (vemurafenib) met its primary endpoint, providing a statistically significant increase in progression-free survival (PFS) compared to Zelboraf alone for patients with previously untreated BRAF-positive metastatic melanoma.